November 13, 2025

Press Release
SUZUKEN CO., LTD.
Shigeru Asano, President and CEO
(Stock Code: 9987)
Securities Traded: Prime Markets of the Tokyo and Nagoya Stock Exchanges, and the Sapporo Securities Exchange
Contact: Yuichi Yamamoto, Executive Officer, Senior General Manager of Corporate Group Planning Headquarters
Tel.: +81-52-961-2331

Suzuken Announces Variances between Forecasts and Actual Consolidated Results for the Six Months Ended September 30, 2025

Suzuken Co., Ltd. hereby announces that variances have occurred between the consolidated financial forecasts announced on May 13, 2025 and the actual results for the six months ended September 30, 2025.

1. Variances between Forecasts and Actual Consolidated Results for the Six Months Ended September 30, 2025

(1) Variances between forecasts and actual results for the six months

(April 1, 2025 - September 30, 2025)

	Net sales	Operating profit	Ordinary profit	Profit attributable to owners of parent	Basic earnings per share
Previous forecasts (A)	Millions of yen 1,232,000	Millions of yen 16,000	Millions of yen 17,000	Millions of yen 10,900	Yen 151.25
Actual results (B)	1,219,440	16,958	18,032	16,241	228.09
Change (B-A)	(12,560)	958	1,032	5,341	
Change (%)	(1.0)	6.0	6.1	49.0	
[Reference] Results for the six months ended September 30, 2024	1,197,323	17,101	17,009	20,278	191.98

(2) Reason for variances

For the six months ended September 30, 2025, net sales generally progressed in line with expectations, supported by the expansion of the oncology drug market and contributions from new drugs, including specialty drugs.

Operating profit and ordinary profit both exceeded forecasts, reflecting our responsive initiatives to the Guidelines for the Improvement of Commercial Transaction Practices revised in April 2024, as well as continued efforts to review and control selling, general and administrative expenses in the face of various escalating costs related to pharmaceutical distribution, including logistics outsourcing fees.

Profit attributable to owners of parent also surpassed expectations, as a result of the recording of extraordinary gains, as disclosed in the announcement titled "Suzuken Announces Recording of Extraordinary Gain on Sale of Investment Securities" on October 15, 2025. These gains were generated through the accelerated implementation of the review and reduction of cross-shareholding, which had already been incorporated into the consolidated earnings forecasts for the fiscal year ending March 31, 2026, announced on May 13, 2025.

The consolidated earnings forecasts for the full fiscal year ending March 31, 2026, remains unchanged.

*The forecasts of consolidated financial results listed above has been prepared based on information available as of the date of this announcement. Actual results may differ from forecast figures due to various factors going forward.